Cleocin (Clindamycin) Adverse Reactions
- abdominal pain
- anaphylactoid reactions
- azotemia
- bullous rash
- colitis
- contact dermatitis
- diarrhea
- dysphagia
- erythema
- erythema multiforme
- esophagitis
- exfoliative dermatitis
- fever
- injection site reaction
- leukopenia
- maculopapular rash
- nausea/vomiting
- neutropenia
- odynophagia
- oliguria
- proteinuria
- pruritus
- pseudomembranous colitis
- Stevens-Johnson syndrome
- thrombocytopenia
- urticaria
- vaginitis
- vesicular rash
- xerosis
Cleocin Adverse Reactions
Abdominal pain, esophagitis, and nausea/vomiting can result from oral clindamycin therapy. Administration with food can reduce minor gastric distress. Esophagitis may be associated with odynophagia, dysphagia, and retrosternal pain. Most symptoms resolve within a few days to weeks after discontinuing the drug. Diarrhea, abdominal cramps, and abdominal tenderness may suggest antibiotic-associated colitis, also known as pseudomembranous colitis or Clostridium difficile colitis when specifically associated with overgrowth of Clostridium difficile. While clindamycin is routinely considered by many clinicians to be a cause of pseudomembranous colitis, prior use of this antibiotic was not found to be predictive of Clostridium difficile colitis in one study of adult inpatients. Also, fever, abdominal pain or cramps, leukocytosis, or blood in the stool did not predict which patients were positive for C. difficile toxin. Mild symptoms may disappear with discontinuation of the drug but the development of Clostridium difficile colitis often requires treatment with vancomycin or metronidazole.
Transient neutropenia (leukopenia) and eosinophilia have been reported during clindamycin therapy. Reports of agranulocytosis and thrombocytopenia have been made. No direct relationship to concurrent clindamycin therapy has been made.
Rashes including maculopapular rash, vesicular rash, or bullous rash as well as urticaria have been observed during clindamycin therapy. Rarely, exfoliative dermatitis including erythema multiforme and Stevens-Johnson syndrome, has been reported with systemic clindamycin. Topical application of clindamycin has been associated with burning (11%), pruritus (10%), xerosis (dry skin) (23%), erythema (16%), oiliness/oily skin (18%), and peeling (11%). Xerosis may be attributed to the solvent used in the topical preparation. Alcohol in some topical formulations will irritate the eyes, mucous membranes, or abraded skin resulting in contact dermatitis.
Intramuscular injection of clindamycin can cause an injection site reaction consisting of pain and/or induration.
Although no direct relationship has been established, renal dysfunction evidenced by azotemia, oliguria, and/or proteinuria has been observed in rare instances. Rare cases of polyarthritis have been reported with systemic clindamycin therapy.
Anaphylactoid reactions can result from sensitivity reactions to clindamycin. Any allergic reaction should be monitored carefully. Patients with an allergy to tartrazine dye should be treated cautiously since some oral preparations contain the dye.
In women treated with clindamycin vaginal cream, the following interactions were reoported in >= 1% of patients: vaginal moniliasis, vulvovaginitis, vulvovaginal disorder (vaginal irritation), trichomonal vaginitis. Vaginitis has also been reported rarely with systemic use of clindamycin.
Related entries
Syndicate
|
